HIGH POINT, N.C. — February 13, 2026 — Leads & Copy — vTv Therapeutics Inc. (Nasdaq: VTVT), a biopharmaceutical company focused on developing cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin, will participate in upcoming investor conferences.
Management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 11:20 AM ET. The presentation will be virtual and available via webcast.
The company will also participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 9:50 AM ET in Boston, MA. The format will include a presentation and 1×1 meetings. A webcast link will be available.
vTv Therapeutics is focused on developing oral, small molecule drug candidates for people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. It is currently in a US Phase 3 trial. The company and its development partners are investigating multiple molecules across different indications for chronic diseases.
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator under investigation in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). Non-clinical studies showed cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin. This supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage. The U.S. Food and Drug Administration (FDA) has granted Cadisegliatin Breakthrough Therapy designation.
Cadisegliatin is under investigation, and its safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
Source: vTv Therapeutics
